Wells Fargo’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$160K Sell
30,697
-9,105
-23% -$53.9K ﹤0.01% 4831
2025
Q4
$212K Buy
39,802
+15,037
+61% +$83.6K ﹤0.01% 5034
2025
Q3
$108K Buy
24,765
+4,038
+19% +$13.1K ﹤0.01% 5281
2025
Q2
$62.8K Buy
+20,727
New +$71.5K ﹤0.01% 5428
2024
Q3
Sell
-500
Closed -$1.04K 7076
2024
Q2
$1.04K Sell
500
-70
-12% -$205 ﹤0.01% 6087
2024
Q1
$2.29K Buy
570
+1
+0.2% +$3 ﹤0.01% 6008
2023
Q4
$1.07K Buy
569
+4
+0.7% +$6 ﹤0.01% 6207
2023
Q3
$944 Buy
565
+2
+0.4% +$5 ﹤0.01% 6217
2023
Q2
$1.35K Buy
563
+3
+0.5% +$9 ﹤0.01% 6268
2023
Q1
$1.75K Buy
560
+1
+0.2% +$3 ﹤0.01% 6253
2022
Q4
$1.5K Buy
559
+1
+0.2% +$3 ﹤0.01% 6079
2022
Q3
$1K Sell
558
-8
-1% -$27 ﹤0.01% 6469
2022
Q2
$1K Buy
566
+6
+1% +$22 ﹤0.01% 6608
2022
Q1
$3K Hold
560
﹤0.01% 6601
2021
Q4
$3K Hold
560
﹤0.01% 6825
2021
Q3
$3K Buy
560
+1
+0.2% +$8 ﹤0.01% 6506
2021
Q2
$6K Sell
559
-67,733
-99% -$767K ﹤0.01% 6298
2021
Q1
$1.07M Buy
68,292
+55,182
+421% +$1.02M ﹤0.01% 4194
2020
Q4
$317K Sell
13,110
-3,453
-21% -$74.4K ﹤0.01% 4844
2020
Q3
$279K Buy
16,563
+7,800
+89% +$181K ﹤0.01% 4766
2020
Q2
$257K Buy
8,763
+8,657
+8,167% +$268K ﹤0.01% 4764
2020
Q1
$2K Buy
+106
New +$3.09K ﹤0.01% 6011
2016
Q2
Sell
-31
Closed -$10K 6315
2016
Q1
$10K Buy
31
+12
+63% +$3.87K ﹤0.01% 5694
2015
Q4
$12K Buy
19
+18
+1,800% +$10.6K ﹤0.01% 5702
2015
Q3
$1K Sell
1
-9
-90% -$5.57K ﹤0.01% 6080
2015
Q2
$7K Buy
+10
New +$6.19K ﹤0.01% 5920

Other funds holding TARA

Wells Fargo's TARA Position: Q1 2026 in Review

Wells Fargo reduced its Protara Therapeutics (TARA) stake by 23% in Q1 2026, selling an estimated $53.9K and leaving 30,697 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #4831.

Wells Fargo first reported a position in TARA in Q2 2015 and has held it in 26 quarters since. The position peaked at $1.07M in Q1 2021. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Wells Fargo held 30,697 shares of Protara Therapeutics worth $160K as of Q1 2026.
  • Wells Fargo sold 9,105 Protara Therapeutics shares in Q1 2026, an estimated $53.9K.
  • Protara Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4831 holding.
  • Wells Fargo first reported a position in Protara Therapeutics in Q2 2015 and has held it in 26 quarters since.
  • Wells Fargo's Protara Therapeutics position peaked at $1.07M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.